Multiple Product Candidates Expected to Advance to Clinic in 2018 & 2019

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology and autoimmune pathways.

Our Pipeline of Product Candidates, all based on our proprietary XpressCF Platform, are summarized in the chart below:

Our Discovery and Preclinical Programs